A detailed history of Dn B Asset Management As transactions in United Therapeutics Corp stock. As of the latest transaction made, Dn B Asset Management As holds 7,800 shares of UTHR stock, worth $2.64 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
7,800
Previous 6,592 18.33%
Holding current value
$2.64 Million
Previous $1.51 Million 64.07%
% of portfolio
0.01%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 05, 2024

BUY
$228.26 - $319.04 $275,738 - $385,400
1,208 Added 18.33%
7,800 $2.48 Million
Q1 2024

Apr 12, 2024

SELL
$210.76 - $249.51 $797,937 - $944,644
-3,786 Reduced 36.48%
6,592 $1.51 Million
Q4 2023

Jan 04, 2024

SELL
$214.88 - $256.94 $947,405 - $1.13 Million
-4,409 Reduced 29.82%
10,378 $2.28 Million
Q3 2023

Oct 13, 2023

BUY
$211.82 - $248.24 $3.13 Million - $3.67 Million
14,787 New
14,787 $3.34 Million
Q3 2020

Oct 14, 2020

SELL
$99.9 - $121.13 $9.35 Million - $11.3 Million
-93,555 Closed
0 $0
Q2 2020

Jul 08, 2020

SELL
$92.74 - $125.82 $4 Million - $5.43 Million
-43,135 Reduced 31.56%
93,555 $11.3 Billion
Q1 2020

Apr 17, 2020

BUY
$79.39 - $115.35 $1.43 Million - $2.07 Million
17,954 Added 15.12%
136,690 $13 Million
Q4 2019

Jan 13, 2020

BUY
$78.31 - $95.34 $9.3 Million - $11.3 Million
118,736 New
118,736 $10.5 Million
Q2 2019

Jul 08, 2019

SELL
$76.06 - $120.81 $1.92 Million - $3.05 Million
-25,243 Closed
0 $0
Q1 2019

Apr 11, 2019

BUY
$107.15 - $126.84 $1.02 Million - $1.2 Million
9,487 Added 60.21%
25,243 $0
Q4 2018

Jan 15, 2019

BUY
$101.4 - $128.73 $1.6 Million - $2.03 Million
15,756 New
15,756 $1.72 Million

Others Institutions Holding UTHR

About UNITED THERAPEUTICS Corp


  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $15.4B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track This Portfolio

Track Dn B Asset Management As Portfolio

Follow Dn B Asset Management As and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dn B Asset Management As, based on Form 13F filings with the SEC.

News

Stay updated on Dn B Asset Management As with notifications on news.